Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Cystoid macular edema associated with fingolimod use for multiple sclerosis.
Natalizumab treatment reduces L-selectin (CD62L) in CD4+ T cells.
Genetic burden of common variants in progressive and bout-onset multiple sclerosis.
Association of SNPs rs6498169 and rs10984447 with multiple sclerosis in Saudi Patients: a model of the usefulness of familial aggregates in identifying genetic linkage in a multifactorial disease.
Disparate in vivo efficacy of FTY720 in xenograft models of Philadelphia positive and negative B-lineage acute lymphoblastic leukemia.
Reward responsiveness and fatigue in multiple sclerosis.
Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis (PROMESS)
Inhibition of SLPI ameliorates disease activity in experimental autoimmune encephalomyelitis.
Type I IFN-mediated regulation of IL-1 production in inflammatory disorders.
Premorbid physical activity predicts disability progression in relapsing-remitting multiple sclerosis.
[Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids].
The cost of multiple sclerosis drugs in the US and the pharmaceutical industry: Too big to fail?
Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial.
Histamine and neuroinflammation: insights from murine experimental autoimmune encephalomyelitis.
Noninvasive molecular imaging of neuroinflammation.
Month of Birth Does Not Seem to Interfere with the Development of Multiple Sclerosis Later in Life in Brazilian Patients.
Treatment of human spasticity with delta 9-tetrahydrocannabinol.
Administration of low dose-estrogen attenuates persistent inflammation, promotes angiogenesis and improves locomotor function following chronic spinal cord injury in rats.
Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis.
Regional Cervical Cord Atrophy and Disability in Multiple Sclerosis: A Voxel-based Analysis.
N-Acetylcysteine amide: A Derivative to Fulfill the Promises of N-Acetylcysteine.
Towards establishing MS prevalence in Latin America and the Caribbean.
Inflammatory Response and Chemokine Expression in the White Matter Corpus Callosum and Gray Matter Cortex Region During Cuprizone-Induced Demyelination.
Revisiting The Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures.
Withdrawal of fingolimod treatment for relapsing-remitting multiple sclerosis: report of six cases.
Pages
« first
‹ previous
…
171
172
173
174
175
176
177
178
179
…
next ›
last »